When is meningococcal conjugate vaccine indicated in the management of HIV infection in primary care?

Updated: Apr 09, 2019
  • Author: Jason F Okulicz, MD, FACP, FIDSA; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print
Answer

Answer

ACIP recommends routine immunization with meningococcal conjugate vaccine (serogroups A, C, W, and Y; Menactra or Menveo) for persons aged 2 months or older with HIV infection. HIV-infected children younger than 2 years should receive the vaccine in accordance with the age-appropriate, licensed, multidose schedule (ie, Menveo at age 2, 4, 6, and 12 months). Persons aged 2 years or more with HIV infection who have not been previously vaccinated should receive a 2-dose primary series of MenACWY conjugate vaccine (Menactra or Menveo). Persons aged 2 years or older with HIV infection who have been previously vaccinated with 1 dose of meningococcal conjugate vaccine should receive a booster dose at the earliest opportunity, provided at least 8 weeks have elapsed since the previous dose, and then continue to receive boosters at the appropriate interval throughout life. [17]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!